Search

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

BAUS 2022: Welcome to BAUS 2022. The return of face to face…

What a pleasure it is to write this welcome to the BAUS congress for 2022. The three years that have elapsed since we all met and celebrated together seem like an eternity and I’m sure we are relishing the chance...

The surgical management of female stress urinary incontinence in a post-mesh era

Trends in surgical management of women with stress urinary incontinence (SUI) have changed in recent times, mainly due to the ‘High Vigilance Pause’ placed on the use of mesh for SUI (and prolapse) surgery in July 2018 following an independent...

What is new in lasers for endourology: looking into the future

From the first cystoscopic argon and neodymium-YAG (yttrium-aluminium-garnet) laser used for bladder tumours in 1976 by Staehler et al. [1], lasers have proven to be a versatile and an evolving tool in the therapeutic management of a variety of urological...

Blaedderwaerc and other names

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would explore the history of something...

Consent: your obligations in the modern, post-Montgomery era

There has been so much recent discussion and so much emphasis placed on the fundamental right that we all have to determine what is or is not done to us, the right to self-determination, that it would be either a...

The role of specialist therapeutic radiographers in the treatment and care of men with prostate cancer

The Statement of Intent: Cancer Strategy for England: 2015-2020 indicates that the number of people diagnosed with cancer each year will continue to grow rapidly due to the ageing population. There is also a requirement to diagnose and offer patients...

Prostate cancer survivorship: a new path for uro-oncology

Over two million people in England have a diagnosis of cancer [1]. Of this figure, over 250,000 have been diagnosed with prostate cancer [2]. However, during the next decade, a rapid increase in the number of new cancer diagnoses, as...

Benign prostatic hyperplasia: what are the benefits and harms of various surgical management options?

Benign prostatic hyperplasia (BPH) is characterised by stromal and epithelial prostatic cell hyperplasia. The enlarged prostate may be associated with voiding and storage lower urinary tract symptoms (LUTS). These have been predominantly attributed to bladder outlet obstruction (BOO), assumed to...

Management of RHC in prostate cancer with selective embolisation and hyperbaric oxygen therapy

Prostate cancer is one of the most prevalent malignancies affecting men worldwide. Radiotherapy is a common treatment modality for localised and locally advanced prostate cancer. While radiotherapy can be effective, it may lead to complications such as radiation-induced haemorrhagic cystitis...

The transition from surgeon to manager during the COVID-19 response

Writing this article on the first Sunday in May, when in any other year, I would be wearing my bowler hat in Hyde Park for the annual Cavalry Memorial Parade, a time ‘pre-COVID’ does seem a very distant memory. Having...